Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar Disorder, Manic Clear all
Completed Phase 4 Interventional

Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

NCT00181922
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
ziprasidone (Geodon)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Jun 10, 2026, 6:38 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

NCT06951698
View directory record Official record
Conditions
Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder

NCT00572117
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Dependence
Interventions
Topiramate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jun 10, 2026, 6:38 AM EDT
Recruiting Phase 1 Interventional

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

NCT03522545
View directory record Official record
Conditions
Treatment-resistant Bipolar Depression
Interventions
Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs), Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 3 Interventional

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

NCT00870311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Jun 10, 2026, 6:38 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

NCT03768726
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 3 Interventional

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

NCT00228059
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jun 10, 2026, 6:38 AM EDT
Recruiting Phase 3 Interventional

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

NCT06462586
View directory record Official record
Conditions
Bipolar Disorder, Manic
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Bellflower, California • Culver City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults

NCT00550394
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Abuse
Interventions
quetiapine and placebo, Quetiapine and Topiramate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Theta Burst Stimulation on the Brain, Behavior, and Clinical Symptoms in Adults With Bipolar Disorder

NCT04696471
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Continuous Theta Burst Stimulation (cTBS), Sham Continuous Theta Burst Stimulation (Sham cTBS)
Device
Lead sponsor
Mary Phillips, MD MD (Cantab)
Other
Eligibility
18 Years to 35 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania

NCT00393978
View directory record Official record
Conditions
Bipolar Disorder, Cannabis-Related Disorder
Interventions
Quetiapine and placebo, Quetiapine and Topiramate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

NCT01811147
View directory record Official record
Conditions
Bipolar Disorder, Major Depression
Interventions
Selective Serotonin Reuptake Inhibitor (SSRI)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
15 Years to 30 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jun 10, 2026, 6:38 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jun 10, 2026, 6:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain Mechanisms of Human Motivation

NCT01976975
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 2 Interventional

Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression

NCT00001483
View directory record Official record
Conditions
Bipolar Disorder, Depressive Disorder
Interventions
buproprion (Wellbutrin), sertraline (Zoloft), venlafaxine (Effexor)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020
View directory record Official record
Conditions
Bipolar Disorder
Interventions
divalproex ER, quetiapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Study in Adolescents With Schizophrenia or Bipolar Disorder

NCT00982020
View directory record Official record
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lauderhill, Florida • Bloomfield Hills, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Jun 10, 2026, 6:38 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

NCT06608641
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
Endoxifen enteric-coated tablet (8 mg), Placebo Tablets
Drug
Lead sponsor
Jina Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Cerritos, California • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 6:38 AM EDT
Completed Phase 3 Interventional

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

NCT00422123
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Jun 10, 2026, 6:38 AM EDT